Skip to main content

Kestenberg-Messina Kaitlin M.'s Form 4 filing

Adma Biologics, Inc. (ADMA) · filed Aug 30, 2024

Accession no.
0001140361-24-039822
Filed
Aug 30, 2024
Trade date
Aug 30, 2024
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $408.1K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kestenberg-Messina Kaitlin M.CIK 0002017423Officer (COO and SVP, Compliance)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 30, 2024Common StockMOption exerciseAcquired+8,125$2.35+$19,093.75457,213Direct
Aug 30, 2024Common StockMOption exerciseAcquired+4,375$2.59+$11,331.25461,588Direct
Aug 30, 2024Common StockMOption exerciseAcquired+6,650$5.94+$39,501468,238Direct
Aug 30, 2024Common StockMOption exerciseAcquired+5,000$4.72+$23,600473,238Direct
Aug 30, 2024Common StockSSaleDisposed−24,150$16.90F1−$408,135449,088Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 30, 2024Common StockMOption exerciseDisposed−8,125$2.35−$19,093.753,750Direct
Aug 30, 2024Common StockMOption exerciseDisposed−4,375$2.59−$11,331.250Direct
Aug 30, 2024Common StockMOption exerciseDisposed−6,650$5.94−$39,5010Direct
Aug 30, 2024Common StockMOption exerciseDisposed−5,000$4.72−$23,6000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $16.72 to $17.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)